Abe Yasunobu, Muta Koichiro, Hirase Nobuhisa, Choi Ilseung, Matsushima Takamitsu, Hara Keiichi, Taguchi Fumihiro, Suematsu Eiichi, Shibata Keisuke, Uike Naokuni, Nishimura Junji, Nawata Hajime
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University.
Rinsho Ketsueki. 2002 Feb;43(2):117-21.
Vitamin K2 is reported to induce apoptosis or differentiation of leukemic cell lines in vitro. We administered a vitamin K2 analog, menatetrenone, at 45 mg daily to 23 patients with myelodysplastic syndrome (MDS): 13 patients with RA, 2 with RARS, 6 with RAEB and 2 with RAEB-T. Good response (GR) and partial response (PR) were defined as an increase of hemoglobin concentration exceeding 2 g/dl and 1-2 g/dl without transfusion, respectively. Six of the RA patients showed improvement of anemia (GR, 3 patients; PR, 3 patients). RA patients who did not have a hypocellular bone marrow and were transfusion-independent tended to be responsive to vitamin K2 therapy in combination with vitamin D3 or anabolic steroids. No adverse effect of vitamin K2 was observed, and the time required to obtain the hematological response was short, being 3 months on average. We believe that vitamin K2 therapy has potential as a treatment for patients with MDS.
据报道，维生素K2可在体外诱导白血病细胞系凋亡或分化。我们对23例骨髓增生异常综合征（MDS）患者每日给予45mg维生素K2类似物甲萘醌：13例难治性贫血（RA）患者、2例环形铁粒幼细胞难治性贫血（RARS）患者、6例难治性贫血伴原始细胞增多（RAEB）患者和2例转化型难治性贫血伴原始细胞增多（RAEB-T）患者。良好反应（GR）和部分反应（PR）分别定义为血红蛋白浓度在未输血情况下升高超过2g/dl和1 - 2g/dl。13例RA患者中有6例贫血情况改善（GR，3例；PR，3例）。骨髓细胞不减少且无需输血的RA患者，联合维生素D3或同化类固醇时，往往对维生素K2治疗有反应。未观察到维生素K2的不良反应，获得血液学反应所需时间较短，平均为3个月。我们认为维生素K2治疗对MDS患者具有潜在治疗价值。
